Filtered By:
Specialty: Drugs & Pharmacology
Condition: Heart Failure

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 434 results found since Jan 2013.

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
Conclusion Saxagliptin demonstrated statistically significant and clinically meaningful improvements in glycemic control and a low risk of hypoglycemia in patients with T2DM. However, this positive profile needs to be tempered by the observation of an increased risk of hospitalization for heart failure in the SAVOR trial. Results from ongoing CV outcome trials with other DPP-4 inhibitors may provide additional data on how best to manage patients with T2DM who are at risk for heart failure. Funding AstraZeneca LP.
Source: Advances in Therapy - November 17, 2015 Category: Drugs & Pharmacology Source Type: research

Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events
Existing epidemiologic and clinical trial data suggest that the blood pressure in patients with hypertension at high risk for cardiovascular events because of coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, or heart failure should be reduced to
Source: American Journal of Therapeutics - January 1, 2016 Category: Drugs & Pharmacology Tags: Therapeutic Reviews Source Type: research

Valacyclovir and Acyclovir Neurotoxicity With Status Epilepticus
We present the case of a 52-year-old man with hypertension, diastolic congestive heart failure, end-stage renal disease on hemodialysis 3 times a week and a remote history of a hemorrhagic stroke who presented to the emergency department with a vesicular rash on his left arm. The rash was observed to be in a dermatomal distribution, and a diagnosis of herpes zoster was made. The patient was discharged home on valacyclovir 1 g 3 times a day for a duration of 7 days. The patient took 2 doses of valacyclovir before presenting to the hospital again with irritability and hallucinations. Over the next several days, the patient's...
Source: American Journal of Therapeutics - January 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
This study will provide essential dosing information for the requisite phase III trials which will investigate whether the beneficial effects of omecamtiv mecarbil translate into improved clinical outcomes. PMID: 26587768 [PubMed - in process]
Source: Expert Opinion on Investigational Drugs - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Sitagliptin and other 'gliptins'- why prescribe them?
Authors: Doggrell SA, Dimmitt SB Abstract INTRODUCTION: In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors ('gliptins'). At present, there is contradictory evidence on whether the gliptins increase hospitalizations for heart failure. Areas covered: This is an evaluation of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in high risk cardiovascular subjects with type 2 diabetes [1]. TECOS demonstrated non-inferiority for sitagliptin over placebo for the primary ...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Long-term administration of angiotensin (1–7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling.
In this study, 8 week-old db/db mice were administered A[1–7] daily via subcutaneous injections. After 16 weeks of treatment, echocardiographic assessment of heart function demonstrated significant improvement in cardiac output, stroke volume and shortening fraction in diabetic animals. A[1–7] also prevented cardiomyocyte hypertrophy, apoptosis, lipid accumulation, and decreased diabetes-induced fibrosis and OS in the heart tissue. Treatment with A[1–7] reduced levels of circulating proinflammatory cytokines that contribute to the low grade inflammation observed in diabetes. In addition, lung pathologies associated w...
Source: Pharmacological Research - March 6, 2016 Category: Drugs & Pharmacology Source Type: research

Atypical chest pain in ACS: a trap especially for women.
Abstract Not all acute coronary syndromes (ACS) exhibit the classic symptoms of chest pain. The diagnosis of ACS in patients without typical chest pain is often challenging. These patients are at increased risk for delayed or incorrect diagnosis, less aggressive treatment and high in-hospital mortality. The association between diabetes mellitus and absence of chest pain in ischemic heart disease is established. As well, it is known that women, more frequently than men, have atypical presentation. However, there is a lack of standardization in characterizing the population of patients with ACS and atypical presenta...
Source: Current Pharmaceutical Design - March 8, 2016 Category: Drugs & Pharmacology Authors: Ricci B, Cenko E, Varotti E, Puddu PE, Manfrini O Tags: Curr Pharm Des Source Type: research

Traditional Chinese Medicines in the management of cardiovascular diseases: a comprehensive systematic review
ConclusionsCertain TCM compounds appear to have significant anti‐hypertensive effects, and although some are associated in some studies with improved outcomes in coronary heart disease, heart failure and type 2 diabetes mellitus the data are inconsistent and will require large‐scale randomised‐controlled trials to allow full evaluation of any potential therapeutic benefit in these areas.
Source: British Journal of Clinical Pharmacology - May 13, 2016 Category: Drugs & Pharmacology Authors: Kerry Layne, Albert Ferro Tags: Review ‐ Themed Issue Source Type: research

Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes
Background: Positive associations have been observed between cardiovascular disease (CVD) and type 2 diabetes mellitus (DM), but their causal relationship has not been clarified. Nevertheless, guidelines from relevant medical societies recommend using cholesterol lowering medication (statin) for both types of patients. Medicines with several different action mechanisms have been developed, and the effectiveness of different lifestyle modifications has been studied extensively for the prevention of DM, which was successful in improving clinical marker status in relatively short-term treatments, but none have been shown to b...
Source: Pharmacology - June 1, 2016 Category: Drugs & Pharmacology Source Type: research

Targeting the ROS-HIF-1-endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications
Publication date: Available online 2 August 2016 Source:Pharmacology & Therapeutics Author(s): Elise Belaidi, Jessica Morand, Emmanuelle Gras, Jean-Louis Pépin, Diane Godin-Ribuot Obstructive sleep apnea (OSA) is now recognized as an independent and important risk factor for cardiovascular diseases such as hypertension, coronary heart disease, heart failure and stroke. Clinical and experimental data have confirmed that intermittent hypoxia is a major contributor to these deleterious consequences. The repetitive occurrence of hypoxia-reoxygenation sequences generates significant amounts of free radicals, particula...
Source: Pharmacology and Therapeutics - August 2, 2016 Category: Drugs & Pharmacology Source Type: research

Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin
Conclusions: The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation.Pharmacology 2017;99:19-26
Source: Pharmacology - September 21, 2016 Category: Drugs & Pharmacology Source Type: research

Real ‐life use of digoxin in patients with non‐valvular atrial fibrillation: data from the RAMSES study
Summary What is known and objectiveAlthough inappropriate use of digoxin has been described in various populations, a real‐world evaluation of patterns of digoxin prescription has not been well studied in patients with atrial fibrillation (AF). The aim of this study was to identify prevalence, indications and appropriateness of digoxin use in the general population of patients with non‐valvular AF (NVAF) in Turkey. MethodsWe included and classified patients from the RAMSES (ReAl‐life Multicentre Survey Evaluating Stroke prevention strategies in Turkey) study, a prospective registry including 6273 patients with NVAF, ...
Source: Journal of Clinical Pharmacy and Therapeutics - September 26, 2016 Category: Drugs & Pharmacology Authors: M. Biteker, Ö. Başaran, V. Dogan, O. Beton, M. Tekinalp, A. Çağrı Aykan, E. Kalaycıoğlu, I. Bolat, O. TaŞar, Ö. Şafak, M. Kalçık, M. Yaman, C. Kırma Tags: Original Article Source Type: research

Relationship between atrial fibrillation and heart failure.
Authors: Hu CY, Wang CY, Li JY, Ma J, Li ZQ Abstract Heart failure (HF) and atrial fibrillation (AF) are major health issues and often co-exist. HF and AF also share common mechanisms, as well as therapies and treatment strategies. The relationship between AF and HF has not been clarified and, therefore, remains an area of research interest. The choice of optimal treatment is a challenge for AF and HF. Control of rate or rhythm is the most important decision for physicians. New tactics for budgeting and centralized monitoring may have an exciting effect on stroke occurrence. Because it is predicted that AF or HF wo...
Source: European Review for Medical and Pharmacological Sciences - November 24, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

The opposing roles of NO and oxidative stress in cardiovascular disease
Publication date: Available online 15 December 2016 Source:Pharmacological Research Author(s): Rebecca H. Ritchie, Grant R. Drummond, Christopher G. Sobey, T. Michael De Silva, Barbara K. Kemp-Harper Nitric oxide (NO) plays a pivotal role in the maintenance of cardiovascular homeostasis. A reduction in the bioavailability of endogenous NO, manifest as a decrease in the production and/or impaired signaling, is associated with many cardiovascular diseases including hypertension, atherosclerosis, stroke and heart failure. There is substantial evidence that reactive oxygen species (ROS), generated predominantly from NADPH oxi...
Source: Pharmacological Research - December 14, 2016 Category: Drugs & Pharmacology Source Type: research

Hypertensive Crisis: pharmacotherapy and complications.
Authors: Wani-Parekh P, Garcia-Blanco C, Mendez M, Mukherjee D Abstract Cardiovascular diseases (CVD) are the number one cause of death globally compared to any other cause. CVD accounts for approximately 17.3 million deaths per year and are rising. Hypertension is the leading risk factor for cardiovascular diseases. Approximately 80 million people suffer from hypertension in the U.S. While, majority of these individuals are on antihypertensive medications only 54% of individuals with hypertension are optimally controlled. Heart failure and stroke are some of the devastating complications of uncontrolled hypertensi...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 23, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research